• LAST PRICE
    2.0600
  • TODAY'S CHANGE (%)
    Trending Up0.0700 (3.5176%)
  • Bid / Lots
    2.0600/ 11
  • Ask / Lots
    2.1200/ 1
  • Open / Previous Close
    1.9757 / 1.9900
  • Day Range
    Low 1.9650
    High 2.1300
  • 52 Week Range
    Low 0.8401
    High 2.9900
  • Volume
    6,338
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.99
TimeVolumeERNA
10:35 ET10001.9757
10:39 ET1701.9767
11:09 ET1001.98
11:29 ET2001.99
11:49 ET1001.97
01:39 ET2521.965
02:08 ET22952.06
02:20 ET1562.13
02:24 ET10002.0847
03:48 ET4072.06
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesERNA
Eterna Therapeutics Inc
10.8M
-0.5x
---
United StatesMNPR
Monopar Therapeutics Inc
10.8M
-1.2x
---
United StatesALLR
Allarity Therapeutics Inc
10.6M
0.0x
---
United StatesGCTK
GlucoTrack Inc
11.1M
-1.1x
---
United StatesENZC
Enzolytics Inc
11.2M
0.0x
---
United StatesABVC
ABVC Biopharma Inc
11.2M
-0.4x
---
As of 2024-05-24

Company Information

Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.

Contact Information

Headquarters
1035 Cambridge Street, Suite 18ACAMBRIDGE, MA, United States 02141
Phone
212-582-1199
Fax
302-655-5049

Executives

Chairman of the Board
James Bristol
President, Chief Executive Officer
Sanjeev Luther
Chief Financial Officer
Sandra Gurrola
Independent Director
Peter Cicala
Independent Director
Dorothy Clarke

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.8M
Revenue (TTM)
$115.0K
Shares Outstanding
5.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
4.46
EPS
$-4.25
Book Value
$0.41
P/E Ratio
-0.5x
Price/Sales (TTM)
93.6
Price/Cash Flow (TTM)
---
Operating Margin
-18,787.83%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.